The anti-CD20 chimaeric monoclonal antibody Rituximab has recently been shown to induce significant clinical response in a proportion of patients with refractory chronic graft-versus-host disease (cGVHD). We now report 38 patients, median age 48 years (22–61), receiving Rituximab for refractory cGVHD, assessed for clinical response and survival. Median duration of cGVHD before Rituximab was23 months(range 2–116), the median number of failed treatment lineswas3 (range 1 to X6) and the median follow-up after Rituximab was11 months (1–88). Overall response rate was 65%: skin 17/20 (63%), mouth 10/21 (48%), eyes6/14 (43%), liver 3/12 (25%), lung 3/8 (37.5%), joints4/5, gut 3/4, thrombocytopaenia 2/3, vagina 0/2, pure red cell aplasia 0/1 and, myasthenia gravis 1/1. During the study period 8/38 died: causes of death were cGVHD progression (n¼3), disease relapse (n¼1), infection (n¼3), sudden death (n¼1). The actuarial 2 year survival is currently 76%. We confirm that Rituximab iseffe ctive in over 50% of patientswith refractory cGVHD and may have a beneficial impact on survival.
Treatment of refractory chronic GVHD with rituximab: a GITMO study / F. Zaja, A. Bacigalupo, F. Patriarca, M. Stanzani, M.T. Van Lint, C. Filı`, R. Scime`, G. Milone, M. Falda, C. Vener, D. Laszlo, P.E. Alessandrino, F. Narni, S. Sica, A. Olivieri, A. Sperotto, A. Bosi, F. Bonifazi , R. Fanin. - In: BONE MARROW TRANSPLANTATION. - ISSN 0268-3369. - 40:3(2007 Aug), pp. 273-277.
Treatment of refractory chronic GVHD with rituximab: a GITMO study
C. Vener;
2007
Abstract
The anti-CD20 chimaeric monoclonal antibody Rituximab has recently been shown to induce significant clinical response in a proportion of patients with refractory chronic graft-versus-host disease (cGVHD). We now report 38 patients, median age 48 years (22–61), receiving Rituximab for refractory cGVHD, assessed for clinical response and survival. Median duration of cGVHD before Rituximab was23 months(range 2–116), the median number of failed treatment lineswas3 (range 1 to X6) and the median follow-up after Rituximab was11 months (1–88). Overall response rate was 65%: skin 17/20 (63%), mouth 10/21 (48%), eyes6/14 (43%), liver 3/12 (25%), lung 3/8 (37.5%), joints4/5, gut 3/4, thrombocytopaenia 2/3, vagina 0/2, pure red cell aplasia 0/1 and, myasthenia gravis 1/1. During the study period 8/38 died: causes of death were cGVHD progression (n¼3), disease relapse (n¼1), infection (n¼3), sudden death (n¼1). The actuarial 2 year survival is currently 76%. We confirm that Rituximab iseffe ctive in over 50% of patientswith refractory cGVHD and may have a beneficial impact on survival.File | Dimensione | Formato | |
---|---|---|---|
1705725a.pdf
accesso aperto
Tipologia:
Pre-print (manoscritto inviato all'editore)
Dimensione
113.16 kB
Formato
Adobe PDF
|
113.16 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.